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1. INTRODUCTION {#mgg3756-sec-0005}
===============

Endometriosis is characterized by the presence of endometrium‐like tissues (including glandular and stromal tissues) outside the uterine cavity, associated with dysmenorrhea, chronic pelvic pain, and infertility (Borghese, Zondervan, Abrao, Chapron, & Vaiman, [2017](#mgg3756-bib-0005){ref-type="ref"}; Giudice, [2010](#mgg3756-bib-0017){ref-type="ref"}; Shafrir et al., [2018](#mgg3756-bib-0043){ref-type="ref"}; Tomassetti & D\'Hooghe, [2018](#mgg3756-bib-0048){ref-type="ref"}) . As a common estrogen‐dependent gynecologic disorder, it affects up to 10% women of reproductive age and up to 50% of women with pelvic pain and/or infertility (Giudice, [2010](#mgg3756-bib-0017){ref-type="ref"}; Shafrir et al., [2018](#mgg3756-bib-0043){ref-type="ref"}; Tomassetti & D\'Hooghe, [2018](#mgg3756-bib-0048){ref-type="ref"}). Although a benign condition, it shares malignant biological behaviors like tissue invasion, local spread, distant metastasis, and relapse, and seriously influences women\'s physical and mental health (Matias‐Guiu & Stewart, [2018](#mgg3756-bib-0032){ref-type="ref"}). Unfortunately, up to date there are still no optimal treatments for endometriosis due to the complexity of the pathogenesis and diversity of symptoms. It is widely assumed that ectopic lesions arise through retrograde endometrial fragments during menstruation (Sampson, [1927](#mgg3756-bib-0040){ref-type="ref"}). However, not all the women suffered endometriosis despite most women at reproductive age exhibit some degree of retrograde menstruation (Halme, Hammond, Hulka, Raj, & Talbert, [1984](#mgg3756-bib-0019){ref-type="ref"}). It is postulated that affected women may have certain susceptible factors that contribute to the development and progression of this disease (Asghari, Valizadeh, Aghebati‐Maleki, Nouri, & Yousefi, [2018](#mgg3756-bib-0003){ref-type="ref"}; Borghese et al., [2017](#mgg3756-bib-0005){ref-type="ref"}; Ponandai‐Srinivasan et al., [2018](#mgg3756-bib-0038){ref-type="ref"}).

With the development of high‐throughput sequencing, novel bioinformatics approaches and corresponding experimental validation, a broad spectrum of noncoding RNAs (ncRNAs), including miRNA, long ncRNA, and circRNA have been revealed and shown to play an important participation in various biological processes. Under certain conditions, those ncRNAs demonstrate abnormal expression pattern which may cause the occurrence or progression of multiple diseases (Ankasha, Shafiee, Wahab, Ali, & Mokhtar, [2018](#mgg3756-bib-0002){ref-type="ref"}; Jain, Thakkar, Chhatai, Bhadrac, & Bhadra, [2017](#mgg3756-bib-0021){ref-type="ref"}; Lekka & Hall, [2018](#mgg3756-bib-0028){ref-type="ref"}; Zhang, Yang, & Xiao, [2018](#mgg3756-bib-0061){ref-type="ref"}). Unlike traditional linear RNAs, circRNA is a distinct class of circular‐shaped RNA, where the 3′ and 5′ ends are covalently bond and form a closed continuous loop, thus is resistant to exonuclease digestion (Jeck & Sharpless, [2014](#mgg3756-bib-0022){ref-type="ref"}). This confers stability on circRNAs and makes them very abundant in the cytoplasm of eukaryotic cells (Jeck et al., [2013](#mgg3756-bib-0023){ref-type="ref"}). Their high abundance, stability, and evolutionary conservation between species suggest that circRNAs may have important regulatory roles (Greene et al., [2017](#mgg3756-bib-0018){ref-type="ref"}; Jeck & Sharpless, [2014](#mgg3756-bib-0022){ref-type="ref"}; Jeck et al., [2013](#mgg3756-bib-0023){ref-type="ref"}; Zhang, Yang, et al., [2018](#mgg3756-bib-0061){ref-type="ref"}). As competing endogenous RNA (ceRNA), circRNAs may sequester miRNAs with their own miRNA response elements (MREs) and function as miRNA "sponges," which strongly suppress miRNA activity and result in increased levels of miRNA target genes, thus mediating cell differentiation, proliferation, apoptosis, and material metabolism etc. (Bossi & Figueroa‐Bossi, [2016](#mgg3756-bib-0007){ref-type="ref"}; Greene et al., [2017](#mgg3756-bib-0018){ref-type="ref"}). For example, a circRNA named *ciRS‐7* or *CDR1‐AS* (OMIM\#300898) contains more than 70 selectively conserved miRNA target sites, and regulate the initiation and progression of various malignancies in a miR‐7‐dependent manner (Hansen, Kjems, & Damgaard, [2013](#mgg3756-bib-0020){ref-type="ref"}; Sang et al., [2018](#mgg3756-bib-0041){ref-type="ref"}; Weng et al., [2017](#mgg3756-bib-0053){ref-type="ref"}). Song and Li ([2018](#mgg3756-bib-0046){ref-type="ref"}) investigated circRNAs expression in osteosarcoma and screened 1,152 upregulated and 915 downregulated circRNAs using microarray. Further findings showed that upregulated hsa_circ_001564 in osteosarcoma tissues served as miR‐29c‐3p "sponge" to promote tumor progression. All abovementioned characteristics make circRNAs become important biological regulators for understanding the molecular mechanisms of diseases and identifying effective diagnostic biomarkers and therapeutic targets. However, there is little information available in literatures about the relationship between circRNAs and endometriosis.

In this study, we explored circRNA expression profiles using high throughput RNA‐Seq for six paired ecEM and euEM tissues and discovered 294 differentially expressed circRNAs (146 upregulated and 148 downregulated). Furthermore, nine up‐expressed circRNAs were validated by qRT‐PCR. We also performed a comprehensive bioinformatic analysis of the most four upregulated circRNAs (hsa_circ_0003380, hsa_circ_0020093, hsa_circ_0008016, and hsa_circ_0077837) and discussed their functions in the pathogenesis and progression of endometriosis. This study may provide a new breakthrough point for etiology research and molecular targeted therapy of endometriosis.

2. PATIENTS AND METHODS {#mgg3756-sec-0006}
=======================

2.1. Ethical compliance {#mgg3756-sec-0007}
-----------------------

This study was approved by the Ethics Committee of Shengjing Hospital (Ethics No. 2018PS504K), and written informed consent was obtained from each patient before surgical procedures.

2.2. Clinical specimens acquisition {#mgg3756-sec-0008}
-----------------------------------

Cyst walls of ovarian endometriomas and matched eutopic endometrium samples from the same patient were collected from 30 women (20--44 years old) with a laparoscopic and histological diagnosis of rASRM (the Revised American Society for Reproductive Medicine classification system, 1997) stage III/IV endometriosis at Shengjing Hospital, China Medical University from February 1, 2017 to March 31, 2018. All patients had regular menstrual cycles (21--35 days) and none of them had received gonadotropin‐releasing hormone analogues or other hormonal medications for at least 6 months before surgery. All euEM samples were in the proliferative phase of menstrual cycle confirmed by histological diagnosis. Once removed from the body, tissue samples were frozen in liquid nitrogen immediately and then stored at −80℃ for subsequent experiments. We chose six pairs of ecEM and euEM for high throughput RNA‐Seq at random.

2.3. RNA isolation and quality control {#mgg3756-sec-0009}
--------------------------------------

Total RNA was isolated from about 100mg of tissue with TRIzol agent (TaKaRa, Japan) according to the manufacturer\'s protocol. RNA quantity and quality were measured using Nanophotometer^®^N50 (Implen, Germany; Supplementary Table [S1](#mgg3756-sup-0001){ref-type="supplementary-material"}). Only when the ratio of the absorbance at 260 nm and 280 nm was between 1.8 and 2.2, the total RNA sample was accepted. All RNA samples were stored at −80°C for further use.

2.4. RNA library preparation and circRNA sequencing {#mgg3756-sec-0010}
---------------------------------------------------

A total amount of about 5 μg RNA per sample was used as input material for the RNA sample preparation. First, ribosomal RNA was removed by Epicentre Ribozero™ rRNA Removal Kit (Epicentre, USA). Subsequently, the linear RNA was digested with 3 units of RNase R (Epicentre, USA) per µg of RNA. The sequencing libraries were generated by NEBNext^®^ Ultra™ Directional RNA Library Prep Kit for Illumina^®^ (NEB, USA) following the manufacturer\'s recommendations. First and second strand cDNA were synthesized and modified with adenylation of 3′ ends of DNA fragments. NEBNext Adaptor with hairpin loop structure was ligated to prepare for hybridization. Then 3 μl USER Enzyme (NEB, USA) was used with size‐selected (preferentially 150--200 bp in length), adaptor‐ligated cDNA before PCR. PCR was performed with Phusion High‐Fidelity DNA polymerase, Universal PCR primers, and Index (X) Primer. At last, products were purified (AMPure XP system) and library quality was assessed on the Agilent Bioanalyzer 2100 system. The clustering of the index‐coded samples was performed on a cBot Cluster Generation System using TruSeq PE Cluster Kit v3‐cBot‐HS (Illumia) according to the manufacturer\'s instructions. After clustering, the libraries were sequenced on an Illumina Hiseq 4000 platform and 150 bp paired‐end reads were generated. The RNA‐Seq and data collection were performed by Novogene Co. LTD, Beijing, China.

2.5. RNA‐seq data analysis {#mgg3756-sec-0011}
--------------------------

Clean reads were used for all the downstream analyses. Reference genome and gene model annotation files were downloaded from genome website directly. Index of the reference genome was built using bowtie2 v2.2.8 and paired‐end clean reads were aligned to the reference genome using Bowtie (Langmead, Trapnell, Pop, & Salzberg, [2009](#mgg3756-bib-0027){ref-type="ref"}). The circRNAs were detected and identified using find_circ (Memczak et al., [2013](#mgg3756-bib-0034){ref-type="ref"}) and CIRI2 (Gao, Zhang, & Zhao, [2018](#mgg3756-bib-0015){ref-type="ref"}). After quantile normalization of raw counts using Trans Per Million, differential expression analysis of two groups (matched ecEM vs. euEM) was performed using the DESeq R package (1.10.1) based on the negative binomial distribution. The resulting *p* values were adjusted using the Benjamini and Hochberg\'s approach for controlling the false discovery rate. CircRNA shaving fold change (*FC*, the ratio of the two groups' averages) ≥2 and adjusted *p*‐values (*P~adj~*) *≤* 0.05 are selected as the significantly differentially expressed.

2.6. Construction of circRNA/miRNA interaction network {#mgg3756-sec-0012}
------------------------------------------------------

MiRNA target sites on circRNA were identified using miRNA target prediction software‐Novomagic (Novogene\'s homemade) based on TargetScan (Enright et al., [2003](#mgg3756-bib-0013){ref-type="ref"}) and miRanda (John et al., [2004](#mgg3756-bib-0024){ref-type="ref"}), and circRNA‐miRNA network was further constructed according to the seed match sequences and was drawn using Cytoscape 3.6.1.

2.7. qRT‐PCR {#mgg3756-sec-0013}
------------

The circRNA was chosen for qRT‐PCR when it met all the following criteria: (a) upregulated in ecEM, (b) *FC* \> 4.0, *P* ~adj \< ~0.01, (c) average readcount of each group ＞3, (d) sequence length between 200 and 1000 nt. According to these criteria, nine circRNAs (hsa_circ_0003380, hsa_circ_0020093, hsa_circ_0002198, hsa_circ_0008016, novel_circ_0000153, hsa_circ_0077837, novel_circ_0020048, hsa_circ_0006856, and hsa_circ_0005777) were chosen. *GAPDH*(GeneBank Sequence \#NM_002046.7) was used as a reference. During the qRT‐PCR validation stage, we first recruited 17 matched ecEM and euEM samples and screened out four most differentially expressed circRNAs, then we further expanded the sample number to 30 for validation. The expression level of circRNAs was evaluated by qRT‐PCR using one‐step SYBR^®^ primescript^TM^ RT‐PCR kit (TaKaRa, Japan) on Applied Biosystems 7500 FAST (Applied Biosystems, USA) in a 20 µl reaction volume, including 11.2 µl 2× PCR master mix, 0.4 µl forward/reverse primers (10 µmol/L), 2 µl total RNA, and 6 µl RAase‐free H~2~O. The cycling program was initiated from 42°C for 5 min, 95°C for 10 s, followed by 40 cycles of 95°C for 5 s and 60°C for 34 s, and last 95°C for 15 s, 60°C for 1min and 95°C for 15 s. All the PCR primers were designed and synthesized by Sangon Biotech (Shanghai, China, Table [1](#mgg3756-tbl-0001){ref-type="table"}), and the specificity was verified by a single‐peak on the melting curve. Each sample had three individual technical replicates. The threshold cycle method (2^−ΔΔCT^) was used to calculate relative expression levels normalized to *GAPDH* levels.

###### 

Primers used in this paper

  ------------------------------------------------------------------------------
  circRNA ID           Primers                            Amplicon length (bp)
  -------------------- ---------------------------------- ----------------------
  hsa_circ_0003380     F:5′‐CACACAGTCAGAGAAACCGG‐3′\      197
                       R:5′‐CTTCTTCGCAGCTCAGATTT‐3′       

  hsa_circ_0020093     F:5′‐CTGGTCATGGGAAGTGTACAAC‐3′\    325
                       R:5′‐ATCCCAGCTACATTCTGTAGCA‐3′     

  hsa_circ_0002198     F:5′‐CCTGAAAGAGCCAAAGCTTG‐3′\      240
                       R: 5′‐AAATCGGTGTAAGGTCACCATA‐3′    

  hsa_circ_0008016     F: 5′‐CGTCCCGCAGCCAGTTGA‐3′\       219
                       R: 5′‐TGGAGGTGCAGGACTCCGTG‐3′      

  novel_circ_0000153   F：5′‐CTTGGACATGGTCAGCAGTATG‐3′\   224
                       R：5′‐GCCTTCAATGAGCCAAGTACAT‐3′    

  hsa_circ_0077837     F：5′‐CCTCTGGATCGGAAGACTGA‐3′\     241
                       R：5′‐TGCCAAGGGACAAGTGTTATTT‐3′    

  novel_circ_0020048   F：5′‐ATTTGATCGTCATGAAATCCAG‐3′\   247
                       R：5′‐TCCCTTGAGGAAAATTAGGTCT‐3′    

  hsa_circ_0006856     F：5′‐AGTCCTAGAACTTGCTTGTGCC‐3′\   287
                       R：5′‐ATGTATTGCCTAGTTGGTCGAA‐3′    

  hsa_circ_0002714     F：5′‐TCATTTGGATCAGTACCATCTG‐3′\   273
                       R：5′‐TTTGATTGTTCGTATTGGCACT‐3′    

  GAPDH                F：5′‐CAGGAGGCATTGCTGATGAT‐3′\     138
                       R：5′‐GAAGGCTGGGGCTCATTT‐3′        
  ------------------------------------------------------------------------------

The circRNA ID is in circBase (<http://circbase.org>); GAPDH Genebank Reference Sequence: NM_002046.7
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2.8. Construction of ceRNA network and enrichment analysis {#mgg3756-sec-0014}
----------------------------------------------------------

We constructed a circRNA‐miRNA‐mRNA network based on ceRNA hypothesis using Cytoscape3.6.1 to investigate their interactions. With the known targeted miRNAs of each circRNA, we used the MiRWalk v3.0 (<http://mirwalk.umm.uni-heidelberg.de/>) with the strict screening conditions including three prediction algorithms (Targetscan，MiRDB and mirTarbase) to predict the downstream target genes. Finally, the ceRNA network was depicted using the validated four circRNAs and predicted miRNAs/mRNAs. GO and KEGG analyses further annotated the function and signaling pathways of these genes.

2.9. Statistical analysis {#mgg3756-sec-0015}
-------------------------

For comparisons of circRNAs expression levels between the ecEM and euEM group, the normal distribution of data was first tested, if satisfied, Student\'s *t* test (two‐tailed) was used; otherwise, nonparametric Mann--Whitney *U*‐test was used. The abovementioned statistical analyses were processed with GraphPad Prism7 (GraphPad Software, USA). A value of *P *＜ 0.05 was considered statistically significant.

3. RESULTS {#mgg3756-sec-0016}
==========

3.1. CircRNA expression profiling {#mgg3756-sec-0017}
---------------------------------

A total of 294 circRNAs were detected to be differentially expressed (*FC* ≥ 2.0 and *P* ~adj~ ≤ 0.05) in ecEM compared with matched euEM samples, with 146 upregulated and 148 downregulated. Hierarchical clustering analysis showed the overview of circRNA expression (Figure [1](#mgg3756-fig-0001){ref-type="fig"}a), and the top 20 up‐ and downregulated circRNAs (Figure [1](#mgg3756-fig-0001){ref-type="fig"}b). Table [2](#mgg3756-tbl-0002){ref-type="table"} listed the top 20 up‐ and downregulated circRNAs. The volcano and scatter plots displayed the variation in circRNA expression between ecEM and euEM groups (Figure [1](#mgg3756-fig-0001){ref-type="fig"}c,d). The distribution of circRNAs in human chromosomes was depicted in the cluster‐shaped bar chart (Figure [2](#mgg3756-fig-0002){ref-type="fig"}a). We investigated the general signatures of dysregulated circRNAs and found that the majority originated from the protein coding exons, and some were from introns and intergenic region (Figure [2](#mgg3756-fig-0002){ref-type="fig"}b).

![CircRNA expression patterns in ecEM relative to those in euEM. (a) Hierarchical cluster analysis of all differentially expressed circRNAs. (b) Hierarchical cluster analysis of the top 20 up‐ and downregulated circRNAs. Each column represents a sample and each row represents a circRNA. The color scale indicates relative expression, upregulation (red), and downregulation (blue). (c) Volcano plots demonstrate differential expression between two different conditions. Red points indicated upregulated while the green points indicated downregulated expression. (d) Scatter plots show the difference in the expression of circRNAs between ecEM and euEM. The values plotted on *X* and *Y* axes are the averaged normalized signal values of each group (log2 scaled). *FC* ≥ 2 and *P* ~adj~ ≤ 0.05 were regarded as the differentially expressed circRNAs](MGG3-7-e00756-g001){#mgg3756-fig-0001}

###### 

The top 20 upregulated and downregulated circular RNAs ranked by fold changes

  circRNA ID                          chromosome   Spliced length   circRNA type   Source gene   Fold change   *P~adj~* value
  ----------------------------------- ------------ ---------------- -------------- ------------- ------------- ----------------
  The top 20 upregulated circRNAs                                                                              
  novel_circ_0012511                  chr2         318              Exonic         *SCN7A*       63.2108364    5.424E‐06
  hsa_circ_0067682                    chr3         668              Exonic         *PLOD2*       47.9546895    4.596E‐05
  hsa_circ_0006528                    chr5         496              Exonic         *PRELID2*     41.0326379    0.0001469
  hsa_circ_0007897                    chr3         457              Exonic         *BOC*         40.5828984    0.0001564
  hsa_circ_0002571                    chr14        14,092           Exonic         */*           36.8808500    0.0003091
  novel_circ_0000523                  chr10        34               Exonic         *MKX*         36.3227115    0.0003238
  novel_circ_0022502                  chr9         371              Exonic         *NTRK2*       34.9858588    0.0004293
  hsa_circ_0004712                    chr6         545              Exonic         *PDE7B*       34.3609972    0.0004443
  novel_circ_0002255                  chr12        534              Exonic         *NR1H4*       32.6090386    0.000641
  novel_circ_0009666                  chr1         292              Intergenic     */*           25.8143255    0.0027854
  hsa_circ_0001425                    chr4         1,127            intronic       *HERC6*       25.3620595    0.0032733
  hsa_circ_0004804                    chr9         327              Exonic         *PBX3*        24.4032265    0.0036856
  novel_circ_0018382                  chr6         298              Exonic         *LAMA2*       22.9114999    0.0048829
  novel_circ_004                      chrX         437              Exonic         *ARHGAP6*     22.1586794    0.0058839
  novel_circ_0006272                  chr16        168              Exonic         */*           21.0084818    0.008401
  hsa_circ_0003513                    chr1         463              Exonic         *GCLM*        20.1470960    0.0098272
  hsa_circ_0017639                    chr10        536              Exonic         *SFMBT2*      18.4660066    0.013729
  hsa_circ_0002130                    chr19        195              Exonic         *C3*          18.0960134    0.016081
  hsa_circ_0002131                    chr8         511              Exonic         *BNIP3L*      18.0496630    0.016694
  hsa_circ_0075830                    chr6         523              Exonic         */*           17.9175317    0.015469
  The top 20 downregulated circRNAs                                                                            
  novel_circ_0018621                  chr6         314              Exonic         *ESR1*        120.1172882   8.594E‐09
  novel_circ_0023209                  chrX         371              Intergenic     */*           74.2438696    9.04E‐13
  hsa_circ_0008844                    chr1         299              Exonic         *MFSD2A*      64.7990160    5.172E‐06
  novel_circ_0022200                  chr9         269              Exonic         */*           55.1771869    1.773E‐05
  hsa_circ_0006030                    chr12        392              Exonic         *TMEM120B*    48.1211762    5.376E‐05
  novel_circ_0023207                  chrX         320              Intergenic     */*           44.5946891    2.861E‐09
  hsa_circ_0085173                    chr8         394              Exonic         *GRHL2*       42.2623182    0.0001586
  novel_circ_0001232                  chr11        423              Exonic         *PGR*         39.0567500    0.000236
  novel_circ_0004306                  chr14        245              Exonic         *NPAS3*       35.7061332    0.0004703
  novel_circ_0010653                  chr1         196              Exonic         *FYB2*        35.4201889    0.0004526
  novel_circ_0018629                  chr6         475              Exonic         *ESR1*        35.1974742    0.0004703
  hsa_circ_0038484                    chr16        220              Exonic         *VWA3A*       31.5266506    2.621E‐07
  novel_circ_0013630                  chr2         108              Exonic         *EPCAM*       30.7092208    0.0011808
  novel_circ_0012657                  chr2         95               Intergenic     */*           30.2822396    0.0013858
  novel_circ_0023024                  chrX         234              Exonic         */*           30.2465775    0.001332
  hsa_circ_0057123                    chr2         363              Exonic         *CDCA7*       29.6631520    0.0015094
  novel_circ_0003732                  chr13        327              Exonic         */*           29.1050986    0.0017015
  novel_circ_0018627                  chr6         336              Exonic         *ESR1*        29.0486659    0.0016979
  hsa_circ_0071408                    chr4         463              Exonic         *PALLD*       28.2073651    0.0018081
  hsa_circ_004237082                  chr17        320              Exonic         *SLC47A1*     27.9175416    0.0021405
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![Characteristics of differentially expressed circular RNAs between ecEM and euEM. (a) The cluster shaped bar chart demonstrates chromosome distribution of differentially expressed circRNAs. (b) The histogram demonstrates the circRNA transcription origination](MGG3-7-e00756-g002){#mgg3756-fig-0002}

3.2. Construction of the circRNA*/*miRNA interaction network {#mgg3756-sec-0018}
------------------------------------------------------------

To explore the function of circRNAs, specific binding patterns between circRNAs and miRNAs were bioinformatically predicted using Novomagic software (Novogene\'s homemade) based on TargetScan and miRanda according to the complementary miRNA matching sequence. A total of 2,495 MREs were formulated to bind with the 294 differentially expressed circRNAs. The circRNA/miRNA interaction network of the top 20 up‐and downregulated circRNAs was drawn by Cytoscape3.6.1 (Figure [3](#mgg3756-fig-0003){ref-type="fig"}).

![circRNA/miRNA network analysis. The network comprising the top 20 upregulated (red triangles) and downregulated circRNAs (green inverted arrows) and their target miRNAs (only top 10 included) are presented](MGG3-7-e00756-g003){#mgg3756-fig-0003}

3.3. QRT‐PCR validation for the selected circRNAs {#mgg3756-sec-0019}
-------------------------------------------------

To validate the circRNA sequencing results, qRT‐PCR was used to detect nine upregulated circRNAs which were chosen according to the criteria above mentioned. Five of nine circRNAs (hsa_circ_0003380, hsa_circ_0020093, hsa_circ_0002198, hsa_circ_0008016, hsa_circ_0077837) were significantly overexpressed in 17 ecEM samples, consistent with RNA‐seq data, while novel_circ_0000153 expression level displayed no statistically significant difference between the two groups (*p* \> 0.05; Figure [4](#mgg3756-fig-0004){ref-type="fig"}a). Meanwhile, novel_circ_0020048, hsa_circ_0006856, and hsa_circ_0005777 could not be amplified by qPCR (data not displayed). We further expanded the number of sample to 30 and compared the expression levels of hsa_circ_0003380, hsa_circ_0020093, hsa_circ_0002198, hsa_circ_0008016, and hsa_circ_0077837 in ecEM and euEM groups. The data confirmed that hsa_circ_0003380, hsa_circ_0020093, hsa_circ_0008016, and hsa_circ_0077837 were all significantly overexpressed in the ecEM group (*p* \< 0.001; Figure [4](#mgg3756-fig-0004){ref-type="fig"}b).

![Validation results for the selected circRNAs. (a) The expression levels of the selected circRNAs were analyzed in 17 paired ecEM and euEM tissues by qPCR; (b) Further validation of the four most differentially expressed circRNAs in total 30 paired ecEM and euEM tissues (*p* \< 0.05 considered significant)](MGG3-7-e00756-g004){#mgg3756-fig-0004}

3.4. Construction of ceRNA network {#mgg3756-sec-0020}
----------------------------------

ceRNA network of the four differentially expressed circRNAs hsa_circ_0003380, hsa_circ_0020093, hsa_circ_0008016, and hsa_circ_0077837 in ecEM was constructed based on the ceRNA theory that circRNAs may share a common binding site of MRE with mRNAs so as to regulate each other (Figure [5](#mgg3756-fig-0005){ref-type="fig"}). The ceRNA network contained 48 miRNAs and 296 mRNAs.

![CircRNAs‐miRNAs‐mRNAs network. The ceRNA network was constructed with the four differentially expressed circRNAs. The network consists of 48 miRNAs and 296 mRNAs. The pink to purple square node represents a protein‐coding gene (the deeper color means the mRNA is targeted by more miRNAs), blue round node represents miRNA and red triangle represents a circRNA](MGG3-7-e00756-g005){#mgg3756-fig-0005}

3.5. Enrichment analysis of circular RNA‐targeted genes {#mgg3756-sec-0021}
-------------------------------------------------------

GO and KEGG analysis was applied to annotate the function of circRNA‐targeted genes predicted in the ceRNA analysis. We totally obtained 57 GO terms and the data indicated that these target genes were mainly involved in the biological processes of extrinsic apoptotic signaling pathway, regulation of protein serine/threonine kinase activity, positive regulation of cellular component movement and so on (Figure [6](#mgg3756-fig-0006){ref-type="fig"}a). Additionally, KEGG analysis revealed 41 signaling pathways such as *MAPK* signaling pathway, pathways in cancer, *FOXO* signaling pathway, *RAS* signaling pathway, and *PI3K*‐*AKT* signaling pathway (Figure [6](#mgg3756-fig-0006){ref-type="fig"}b).

![Functional ananlysis for the four validated circRNAs gathering genes. The vertical axis shows the annotated functions of the target genes. The horizontal axes show the enrichment score (−log10 transformed *p*‐value) and the gene number of each cluster, respectively. Only the top 10 significantly enriched clusters are included. (a) GO analysis. (b) KEGG pathway analysis](MGG3-7-e00756-g006){#mgg3756-fig-0006}

4. DISCUSSION {#mgg3756-sec-0022}
=============

Recently, a growing body of evidence indicates that ncRNAs play crucial regulatory roles in the pathogenesis and development of endometriosis, including miRNAs (Agrawal et al., [2018](#mgg3756-bib-0001){ref-type="ref"}; Nothnick, [2017](#mgg3756-bib-0035){ref-type="ref"}) and long ncRNAs (Cui et al., [2018](#mgg3756-bib-0010){ref-type="ref"}; Wang et al., [2016](#mgg3756-bib-0051){ref-type="ref"}). For example, miR‐29c (Long, Wan, La, Gong, & Cai., [2015](#mgg3756-bib-0030){ref-type="ref"}) and miR‐200b (Eggers et al., [2016](#mgg3756-bib-0012){ref-type="ref"}) were reported as downregulated in endometriosis and affecting endometrial cell proliferation, apoptosis, and invasion. LncRNA *LINC00261* downregulation inhibited endometriosis cell growth and migration (Sha et al., [2017](#mgg3756-bib-0042){ref-type="ref"}). Ghazal et al. ([2015](#mgg3756-bib-0016){ref-type="ref"}) proposed that perturbation of *H19/Let‐7/IGF1R* regulatory pathway might represent a potential mechanism for endometriosis‐associated infertility. However, to the best of our knowledge, studies on the identification and functional characterization of circRNAs in endometriosis are limited.

In this study, we investigated circRNA expression profiles in ecEM compared with euEM of endometriosis patients and identified 294 differentially expressed circRNAs, 146 upregulated and 148 downregulated. Most of those dysregulated circRNAs originate from exons or introns which are in accordance with previous researches (Shen et al., [2018](#mgg3756-bib-0044){ref-type="ref"}; Xu et al., [2018a](#mgg3756-bib-0057){ref-type="ref"}, [2018b](#mgg3756-bib-0058){ref-type="ref"}; Zhang, Ren, Xiao, Xia, & Fang, [2018](#mgg3756-bib-0060){ref-type="ref"}). It has been reported that both exonic and intronic circRNAs may exert potential functions in gene regulation (Greene et al., [2017](#mgg3756-bib-0018){ref-type="ref"}). Xu et al. ([2018a](#mgg3756-bib-0057){ref-type="ref"}) revealed for the first time the circRNA expression patterns between women with and without endometriosis and found that the increased level of circ_0004712 and circ_0002198 could help identify the patients with endometriosis. Zhang, Ren, et al. ([2018](#mgg3756-bib-0060){ref-type="ref"}) assessed the expression profiles of circRNAs in endometriosis by microarray analysis and detected 2,237 circRNAs differentially expressed among ectopic endometrium (EC) (endometriotic lesions), paired eutopic endometrium (EU), and normal endometrium from women free of endometriosis, and qRT‐PCR validation suggested that downregulated circ_103470 and circ_101102 matched the microarray results. In our study, four of nine upregulated circRNAs (hsa_circ_0003380, hsa_circ_0020093，hsa_circ_0008016 and hsa_circ_0077837) were confirmed by qRT‐PCR, which was consistent with sequence assays. Hsa_circ_0003380 is derived from the *ZFPM2* gene. *ZFPM2* is known as an inhibitor of *PI3K/AKT* pathway (Xiao et al., [2014](#mgg3756-bib-0054){ref-type="ref"}). Previous studies have demonstrated that activating *PI3K/AKT* pathway lead to cellular events including proliferation, invasion, and angiogenesis in developing endometrial lesions (Cao et al., [2017](#mgg3756-bib-0008){ref-type="ref"}; Diao et al., [2017](#mgg3756-bib-0011){ref-type="ref"}). Hsa_circ_0020093 is encoded by *ATRNL1* which is a highly conserved transmembrane protein involved in cell adhesion and signaling events (Stark et al., [2010](#mgg3756-bib-0047){ref-type="ref"}). *EP* *B41L2* gene is the parental gene of hsa_circ_0077837 that encodes 4.1G protein, which is a membrane skeletal protein that can also serve as an adapter to mediate cell adhesion, migration, and apoptosis in tumorgenesis (Bosanquet, Ye, Harding, & Jiang, [2014](#mgg3756-bib-0006){ref-type="ref"}). At the initial stages of endometriosis, the attachment of retrograde endometrial tissues onto the pelvic mesothelium is a critical step and cell adhesion molecules are taken as key factors in this process (Kuessel et al., [2017](#mgg3756-bib-0026){ref-type="ref"}; Tsai et al., [2018](#mgg3756-bib-0049){ref-type="ref"}). *FGFR1* is the source gene of hsa_circ_0008016. Zhao et al. ([2015](#mgg3756-bib-0062){ref-type="ref"}) found that *FGFR1* was overexpressed in ectopic endometrium of endometriosis and correlated with dysmenorrhea severity and recurrence of this disease. Considering the various functions of those parent genes, we speculated that dysregulation of these circRNAs might play a role in the development and progression of endometriosis.

CircRNAs can function as miRNA sponge through the ceRNA network. Based on the ceRNA hypothesis, circRNAs can affect the miRNA activity through sequestration, thereby increasing or decreasing miRNA target gene expression (Bossi & Figueroa‐Bossi, [2016](#mgg3756-bib-0007){ref-type="ref"}; Greene et al., [2017](#mgg3756-bib-0018){ref-type="ref"}). We constructed the ceRNA crosstalk network to further explore the role of dysregulated circRNAs in endometriosis. The four validated upregulated circRNAs (hsa_circ_0003380, hsa_circ_0020093，hsa_circ_0008016, and hsa_circ_0077837) were found to target 48 miRNAs, of which 26 miRNAs have been reported in previous studies that might be associated with endometriosis (Agrawal et al., [2018](#mgg3756-bib-0001){ref-type="ref"}; Long et al., [2015](#mgg3756-bib-0030){ref-type="ref"}; Nothnick, [2017](#mgg3756-bib-0035){ref-type="ref"}). Ohlsson‐Teague and coworkers ([2009](#mgg3756-bib-0036){ref-type="ref"}) first assessed the miRNA expression profiles in paired eutopic and ectopic endometrial tissues in 2009 and identified 14 upregulated and 8 downregulated miRNAs specific to endometriotic lesion by microarray analysis. For example, miR‐143 was reported as upregulated in eutopic endometrial tissues (Ohlsson‐Teague et al., [2009](#mgg3756-bib-0036){ref-type="ref"}). Another study in vitro showed that expression of miR‐27b‐3p was significantly higher in human endometrial stromal cells from patients with endometriosis than that of controls, which was related to fibrosis modulation (Kim et al., [2017](#mgg3756-bib-0025){ref-type="ref"}). miR‐34a‐5p was significantly downregulated in patients with endometriosis (Ma, Huang, & Chen, [2017](#mgg3756-bib-0031){ref-type="ref"}). Additionally, several studies have published that miRNAs as putative biomarkers of endometriosis in biofluids. Seral miR‐125b‐5p levels, combined with miR‐451a and miR‐3613‐5p distinguished subjects with endometriosis from those without (Cosar et al., [2016](#mgg3756-bib-0009){ref-type="ref"}). Expressions of miR‐200a‐3p and miR‐141‐3p were also downregulated in plasma samples of endometriosis patients (Rekker et al., [2015](#mgg3756-bib-0039){ref-type="ref"}).

MiRNAs can regulate a wide array of biological processes through post‐transcriptionally repressing downstream mRNAs expression. Through bioinformatic prediction, there are 296 mRNAs targeted by the 48 miRNAs. In our study, bioinformatics analysis presented that E2F transcription factor 3 (*E2F3*), one target of miR‐141‐3p, is oncogenic in tumorigenesis and corresponds with poor prognosis in various cancers (Gao et al., [2017](#mgg3756-bib-0014){ref-type="ref"}). Considering that endometriosis shares many characteristics with malignant diseases, we hypothesized that the miR‐141‐3p*/E2F3* axis might play a role in the pathogenesis of endometriosis. Previous studies demonstrated that the miR‐200 family members (miR‐200a‐3p and miR‐141‐3p) regulated a cohort of target genes such as *ZEB1* and E‐cadherin involved in epithelial‐mesenchymal transition (EMT) and metastasis (Bhardwaj et al., [2017](#mgg3756-bib-0004){ref-type="ref"}; Xiong et al., [2016](#mgg3756-bib-0056){ref-type="ref"}), which are important events in the initiation and progression of endometriosis. Thus, we inferred that hsa_circ_0020093/miR‐141‐3p/miR‐200a‐3p/ *ZEB1* axis might regulate EMT in endometriosis. Angiogenesis is one of the important pathophysiological conditions in endometriosis and *VEGFA* was ever reported to be upregulated in endometriotic tissues (Ma et al., [2017](#mgg3756-bib-0031){ref-type="ref"}). By constructing the ceRNA network, we supposed that hsa_circ_0003380*/*miR‐205*/ VEGFA* axis might modulate the angiogenic process in endometriosis. *CDK6*, predicted as a common target gene of miR‐103a‐3p, miR‐34c‐5p, miR‐449a, and miR‐449b‐5p, mainly serves as an oncogenic kinase that regulates cell cycle and was found upregulated in endometriosis (Wang, Li, Yang, Liu, & Wang, [2015](#mgg3756-bib-0052){ref-type="ref"}). Genetic studies have demonstrated that endometriotic lesions commonly have mutations in genes, particularly the *TP53*, *KRAS*, *PTEN*, and *ARID1A* genes, which suggest a direct transition from a subset of endometriotic lesions to invasive neoplasms (Matias‐Guiu & Stewart, [2018](#mgg3756-bib-0032){ref-type="ref"}; Ponandai‐Srinivasan et al., [2018](#mgg3756-bib-0038){ref-type="ref"}). Lin et al. ([2017](#mgg3756-bib-0029){ref-type="ref"}) identified that disruption of hypoxia‐induced *YAP1* signaling by siRNA knockdown or inhibitor abolished critical biological processes in endometriosis development like steroidogenesis, angiogenesis, inflammation, migration, innervation, and cell proliferation.

To further dissect the role of those target genes contained in the ceRNA network, we also performed GO and KEGG analysis and obtained 57 functional terms and 41 important signaling pathways, most of which were consistent with the current knowledge on endometriosis. For example, the most significant GO term of biological process is extrinsic apoptotic signaling pathway (GO:0097191) which enriched 22 differentially expressed genes such as *BCL2L11*, *YAP1, PTEN*, and *PIK3R1*. Once mutated, these abnormal molecules can influence the cell survival through cascading activation of kinase signaling pathways and may cause malignant ovarian tumors (Matias‐Guiu & Stewart, [2018](#mgg3756-bib-0032){ref-type="ref"}; Ponandai‐Srinivasan et al., [2018](#mgg3756-bib-0038){ref-type="ref"}). Song et al. ([2016](#mgg3756-bib-0045){ref-type="ref"}) highlighted that dysregulation of *HIPPO*/*YAP1* pathway components or amplification of its downstream effector *YAP1* resulted in increased endometrial stromal cell proliferation and decreased cell apoptosis. Through KEGG analysis, we found that target genes participated in several signal pathways which were well‐researched in many diseases, such as *MAPK* signaling pathway, pathways in cancer, *FOXO* signaling pathway, *RAS* signaling pathway, and *PI3K‐AKT* signaling pathway. Xu et al. ([2018b](#mgg3756-bib-0058){ref-type="ref"}) constructed a circRNA‐miRNA‐mRNA network based on five identified differentially expressed circRNAs and eight mRNAs between ovarian ectopic and paired eutopic endometria, and revealed the primary roles of cancer‐related, purine metabolism, glycerophospholipid metabolism, and thyroid hormone signaling pathways in endometriosis pathogenesis. As outlined in many articles, the establishment and progression of endometriosis requires a number of signal pathways regulating cooperatively, like the canonical *IKKβ/NF‐κB* pathway, the *MAPK* pathways, and the *PI3K/AKT/mTOR* pathway, which also have been taken as viable targets for endometriosis treatment (McKinnon, Kocbek, Nirgianakis, Bersinger, & Mueller, [2016](#mgg3756-bib-0033){ref-type="ref"}). Genome‐wide association study uncovered top pathways significantly associated with endometriosis and stage A disease included several *MAPK*‐related pathways (Uimari et al., [2017](#mgg3756-bib-0050){ref-type="ref"}). Endometriosis lesions exist in a unique microenvironment and demonstrate a series of malignant biological behaviors. Pathways in cancer may also involve in pathogenesis and progression of endometriosis. Cao et al. ([2017](#mgg3756-bib-0008){ref-type="ref"}) first revealed a dose‐dependent inhibition effect of ginsenoside Rg3 on the growth of ectopic endometrium in endometriosis rats through blocking *VEGFR*‐2‐mediated *PI3K/AKT/mTOR*signaling pathway. Increased activation of *RAS/RAF/MAPK* and *RhoA/ROCKII* signaling pathways in primary eutopic endometrial stromal cells of patients with endometriosis promoted cell proliferation and migration (Yotova et al., [2011](#mgg3756-bib-0059){ref-type="ref"}). Cross‐talk between *FOXO* signaling pathway and other pathways like *PI3K‐AKT*, *MAPK*, *β‐CATENIN/WNT* involves in cell differentiation, proliferation, and apoptosis which may provide a new avenue for the prevention and treatment of diseases (Parker et al., [2012](#mgg3756-bib-0037){ref-type="ref"}; Xing et al., [2018](#mgg3756-bib-0055){ref-type="ref"}). Certainly, the role of *FOXO* signaling pathway in endometriosis deserves further exploration. Future studies are expected to clearly define the functions of those signaling pathways in endometriosis pathophysiology.

In conclusion, our study revealed that the circRNA expression profiles in ovarian endometriosis and obtained 294 differentially expressed circRNAs between paired ecEM and euEM. The ceRNA network and functional analysis of potential target genes highlighted the relationship between dysregulated circRNAs and ovarian endometriosis, which may provide a new perspective on researches of endometriosis. However, there were several limitations existing in this study. First, the sample size was small and only rASRM stage III/IV cases were included. Second, the tissue samples were only derived from ectopic endometrioma wall and eutopic endometrium, neither peritoneal lesions nor deep infiltrated endometriosis, thus further validation involving in larger cohorts of patients with early stages as well as other types of endometriosis is warranted. Third, the tissue RNA isolation relied on the removal of ribosomal RNA by rRNA Removal Kit and a digest of free RNA by RNase R, and this approach had certain limitations as some other RNA types except circular RNAs could have been preserved which might interfered with the final data, therefore new RNA purification methods are expected. And then validation of the RNA‐seq assays by qRT‐PCR using specific primers is essential. Fourth, the molecular mechanism and function of the present circRNAs should be tested in vivo and vitro experiments further. Our group has started to study the overall effect and in‐depth mechanism of hsa_circ_0003380 and hsa_circ_0020093 in endometriosis, which may be promising biomarkers and therapeutic targets of endometriosis.
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